市場調査レポート

商品コード

ポイントオブケア分子診断薬市場- 成長、将来展望、競争分析、2023年～2031年

Point of Care Molecular Diagnostics Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

出版日: 2023年04月10日 | 発行: Acute Market Reports

| ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格

PDF (Single User License)

USD 4,500 705,420円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 6,500 1,018,940円

レポートPDFを10名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 9,000 1,410,840円

レポートPDFを企業内すべての方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ポイントオブケア分子診断薬の世界市場は、2023年から2031年の予測期間中にCAGR 8.5％で拡大すると予測されています。ポイントオブケア分子診断薬市場の上昇は、主に感染症やがんの有病率の増加、およびその魅力的な特徴からエンドユーザーのポイントオブケア分子検査に対する要望が高まっていることに起因します。医療関係者は、検査室やその他のヘルスケア環境において、長い間分子診断法を活用してきました。しかし、分子診断の高価な検査費用、時間のかかる検査、所見の遅れが、代替の診断方法を模索するきっかけとなっています。このような背景から、ポイントオブケア型の分子診断薬市場が脚光を浴びています。ポイントオブケア分子診断薬は、所要時間を短縮し、信頼性の高い結果を迅速に提供できることから、病院や研究機関を含む最終用途の垂直方向で大きな支持を集めています。ポイントオブケアでの分子検査は、検査室以外の場所での病気の迅速かつ早期診断を可能にします。一般的に、これらの検査は身近な患者のいる場所で実施されます。

ポイントオブケア分子診断市場の成長を促進する主な要因は、呼吸器疾患やがんから性感染症や消化器疾患まで、幅広い疾患の早期発見のためにポイントオブケア分子診断ソリューションの採用が増加していることです。今後、新興国の健康意識の高まりに後押しされ、分子診断薬や分子イメージング市場が急速に拡大することで、ポイントオブケア分子診断薬メーカーに可能性が生まれると考えられます。また、近年のマイクロ流体技術や遺伝子配列解析の進歩に加え、低コストでスピーディーなPOC分子診断プラットフォームの開拓により、POC分子診断装置の販売が拡大し、分子POC検査市場は拡大すると考えられます。

感染症や悪性疾患の頻度の増加

先進国、新興国を問わず、感染症やがんの発症率が上昇していることは、ポイントオブケア分子診断薬市場の成長に好影響を与えるでしょう。分子診断薬の処方頻度の増加は、こうした疾患の診断と治療に起因しています。ポイントオブケア分子診断薬に対する需要は、上記のような原因や予防医学の傾向の高まりによって、予測期間中に促進されると予想されます。

新興国における事業拡大のチャンス

インド、韓国、ブラジル、メキシコなどの新興国は、ポイントオブケア分子診断分野での市場参入企業に大きな成長の可能性をもたらしています。これは、規制のハードルが低いこと、ヘルスケアインフラの進歩、患者数の増加、感染症の流行、医療費の増加などに起因しています。また、これらの国の規制政策は、先進国のそれよりも適応性が高く、ビジネスに適しています。

不利な償還シナリオが市場成長を制限する

診療所における分子診断薬市場の成長を阻害する主要因は、不十分な診療報酬です。メディケアや民間の医療保険者に診断検査費用を支払ってもらうことは、ほとんどの診断検査の商業化にとって大きな障害となっています。2018年、米国のメディケアは、ポイントオブケア分子診断薬を含むいくつかのIVD検査に対する資金提供プロセスを更新しました。これらの検査のいくつかは、未登録のヘルスケア共通手続きコーディングシステム（HCPCS）コードを使用して請求されます。このような場合、メディケア管理契約者（MAC）は、それぞれの自治体に対する支払額を設定します。CMSは、ハイスループット技術に基づくCOVID-19検査のメディケア支払率を、検査室が2日以内に所見を処理できない限り75米ドルに引き下げました。メディケアは現在、がんの家族歴がない人に対する遺伝子検査に資金を提供していない（出典：米国臨床腫瘍学会（American Society of Clinical Oncology））。

アプリケーション別では、感染症が市場をリードする

分子診断におけるPoC検査は、感染症管理、腫瘍学、血液学、出生前スクリーニング、内分泌学などにおいて、患者の近くで検査を行うなど、多くの用途があります。感染症や腫瘍学の分野では、ポイントオブケア（PoC）分子検査は、アプリケーションベースの進歩が最も大きいです。2022年には、感染症分野の収益シェアが最も大きくなりました。感染症の迅速分子診断検査の収益シェアに寄与しているのは、適切な抗生物質療法の提供と促進、疾病管理の迅速化、ヘルスケアラボ資産の分配強化、死亡率とヘルスケア支出の削減です。

技術別ではPCRベースの検査が市場をリード

技術別に見ると、ポイントオブケア分子診断の市場は、PCRベース、遺伝子配列ベース、ハイブリダイゼーションベース、マイクロアレイベースの検査とデバイスに分けられます。2022年には、PCRベースの検査が最大の収益シェアを獲得しました。H1N1やインフルエンザなどの感染症に対して、正確で迅速なリアルタイムPCR分析を実現するポイントオブケア診断の商品化が、市場を牽引することになるでしょう。業界の多くの進歩により、患者に近接したNGSベースの分子検査は、予測期間中に大幅な成長が見込まれます。遺伝子配列決定とDNAデータ処理をポイントオブケアで高精度に行い、迅速な診断を可能にする革新的なプラットフォームの改良が、この市場分野の成長予測に寄与しています。迅速DNA解析は、市場リーダーの継続的な技術革新と研究開発努力の結果、今後数年間で大きな成長を遂げると予測されます。

検査部位別市場では、予測期間中、OTC検査が主流を占める

市場は、検査を行う場所によって、概念実証（PoC）検査と店頭（OTC）検査に分けられます。OTC検査の汎用性と携帯性は、家庭や福祉施設での使用においてPOC検査より優れています。OTCの利用者の大半は、訓練を受けていない専門家であり、大半の場合、患者自身です。さらに、これらの検査機器の多くはCLIAが免除されているため、検査室以外での使用が奨励されています。市販（OTC）検査は、その使い勝手の良さ、アクセスしやすさ、採用率の高さから、予測期間中に多くの収益を上げると予想されています。

エンドユーザー別では、分散型検査室が市場をリード

市場は、エンドユース別に、分散型ラボ、病院、在宅ケア、生活支援型ヘルスケア施設などに区分されます。2022年には、分散型検査室が最大の収益シェアを獲得しました。これらの検査は、中央検査室ベースの同等品よりも物理的な設置面積が大幅に小さく、迅速かつ正確な分子分析を提供できることが、このセグメントの収益シェアを拡大する重要な促進要因となっています。

APACは引き続き最速の成長地域となる

市場参入企業の継続的な取り組みが、市場シェアの拡大に大きく寄与しています。また、新規分子検査の有効性と精度を検証する多くの臨床研究が、予測期間を通じて市場の拡大に寄与すると予想されます。迅速な診断へのニーズの高まりと、DNA解析のための革新的な分子診断法のイントロダクションより、欧州は重要な市場ニッチとして位置づけられています。アジア太平洋は、高度な中央研究所検査サービスの欠如、臨床検査を必要とする人口の多さ、PoC分子アッセイの費用対効果の高い導入の可能性などから、予測期間中に最も高い成長率を記録すると予測されます。

市場のスナップショット：世界のポイントオブケア分子診断薬市場
世界のポイントオブケア分子診断薬市場：製品・サービス別 2022
世界のポイントオブケア分子診断薬市場：技術別 2022
世界のポイントオブケア分子診断薬市場：用途別 2022
世界のポイントオブケア分子診断薬市場：エンドユーザー別 2022
世界のポイントオブケア分子診断薬市場：地域別 2022
魅力的な投資提案：地域別 2022

第3章ポイントオブケア分子診断薬市場：競合分析

主要ベンダーの市場ポジショニング
ベンダーが採用する戦略
主要な産業戦略
ティア分析：2022 vs. 2031

第4章ポイントオブケア分子診断薬市場：マクロ分析と市場力学

イントロダクション
世界のポイントオブケア分子診断薬市場金額 2021-2031
市場力学
- 市場促進要因
- 市場抑制要因
- 主な課題
- 主な機会
促進要因と抑制要因の影響分析
シーソー分析

第5章ポイントオブケア分子診断薬市場：製品・サービス別 2021-2031

市場概要
成長・収益分析：2022 vs. 2031
市場セグメンテーション
- アッセイとキット
- 機器と分析装置
- ソフトウェアとサービス

第6章ポイントオブケア分子診断薬市場：技術別 2021-2031

市場概要
成長・収益分析：2022 vs. 2031
市場セグメンテーション
- RT-PCR
- イナート
- その他の技術

第7章ポイントオブケア分子診断薬市場：用途別 2021-2031

市場概要
成長・収益分析：2022 vs. 2031
市場セグメンテーション
- 呼吸器疾患
- 性感染症
- 院内感染
- がん
- 肝炎
- 胃腸障害
- その他のアプリケーション

第8章ポイントオブケア分子診断薬市場：エンドユーザー別 2021-2031

市場概要
成長・収益分析：2022 vs. 2031
市場セグメンテーション
- 診療所
- 病院とICU
- 調査
- その他のエンドユーザー

第9章北米のポイントオブケア分子診断薬市場 2021-2031

市場概要
ポイントオブケア分子診断薬市場：製品・サービス別 2021-2031
ポイントオブケア分子診断薬市場：技術別 2021-2031
ポイントオブケア分子診断薬市場：用途別 2021-2031
ポイントオブケア分子診断薬市場：エンドユーザー別 2021-2031
ポイントオブケア分子診断薬市場：地域別 2021-2031
- 北米
  - 米国
  - カナダ
  - その他北米地域

第10章英国と欧州連合のポイントオブケア分子診断薬市場 2021-2031

市場概要
ポイントオブケア分子診断薬市場：製品・サービス別 2021-2031
ポイントオブケア分子診断薬市場：技術別 2021-2031
ポイントオブケア分子診断薬市場：用途別 2021-2031
ポイントオブケア分子診断薬市場：エンドユーザー別 2021-2031
ポイントオブケア分子診断薬市場：地域別 2021-2031
- 英国と欧州連合
  - 英国
  - ドイツ
  - スペイン
  - イタリア
  - フランス
  - その他欧州地域

第11章アジア太平洋のポイントオブケア分子診断薬市場 2021-2031

市場概要
ポイントオブケア分子診断薬市場：製品・サービス別 2021-2031
ポイントオブケア分子診断薬市場：技術別 2021-2031
ポイントオブケア分子診断薬市場：用途別 2021-2031
ポイントオブケア分子診断薬市場：エンドユーザー別 2021-2031
ポイントオブケア分子診断薬市場：地域別 2021-2031
- アジア太平洋
  - 中国
  - 日本
  - インド
  - オーストラリア
  - 韓国
  - その他アジア太平洋地域

第12章ラテンアメリカのポイントオブケア分子診断薬市場 2021-2031

市場概要
ポイントオブケア分子診断薬市場：製品・サービス別 2021-2031
ポイントオブケア分子診断薬市場：技術別 2021-2031
ポイントオブケア分子診断薬市場：用途別 2021-2031
ポイントオブケア分子診断薬市場：エンドユーザー別 2021-2031
ポイントオブケア分子診断薬市場：地域別 2021-2031
- ラテンアメリカ
  - ブラジル
  - メキシコ
  - その他ラテンアメリカ地域

第13章中東・アフリカのポイントオブケア分子診断薬市場 2021-2031

市場概要
ポイントオブケア分子診断薬市場：製品・サービス別 2021-2031
ポイントオブケア分子診断薬市場：技術別 2021-2031
ポイントオブケア分子診断薬市場：用途別 2021-2031
ポイントオブケア分子診断薬市場：エンドユーザー別 2021-2031
ポイントオブケア分子診断薬市場：地域別 2021-2031
- 中東・アフリカ
  - GCC
  - アフリカ
  - その他中東・アフリカ地域

第14章企業プロファイル

Abbott Laboratories（U.S.）
F. Hoffmann-La Roche Ltd.（Switzerland）
bioMerieux S.A.（France）
Danaher Corporation（U.S.）
Quidel Corporation（U.S.）
QIAGEN N.V.（Netherlands）
Co-Diagnostics Inc.
Biocartis NV（Belgium）
Meridian Bioscience Inc.（U.S.）
Thermo Fisher Scientific Inc.（U.S.）

図表

List of Tables

TABLE 1 Global Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 2 Global Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 3 Global Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 4 Global Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 5 North America Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 6 North America Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 7 North America Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 8 North America Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 9 U.S. Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 10 U.S. Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 11 U.S. Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 12 U.S. Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 13 Canada Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 14 Canada Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 15 Canada Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 16 Canada Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 17 Rest of North America Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 18 Rest of North America Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 19 Rest of North America Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 20 Rest of North America Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 21 UK and European Union Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 22 UK and European Union Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 23 UK and European Union Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 24 UK and European Union Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 25 UK Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 26 UK Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 27 UK Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 28 UK Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 29 Germany Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 30 Germany Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 31 Germany Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 32 Germany Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 33 Spain Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 34 Spain Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 35 Spain Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 36 Spain Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 37 Italy Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 38 Italy Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 39 Italy Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 40 Italy Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 41 France Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 42 France Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 43 France Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 44 France Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 45 Rest of Europe Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 46 Rest of Europe Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 47 Rest of Europe Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 48 Rest of Europe Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 49 Asia Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 50 Asia Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 51 Asia Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 52 Asia Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 53 China Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 54 China Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 55 China Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 56 China Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 57 Japan Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 58 Japan Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 59 Japan Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 60 Japan Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 61 India Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 62 India Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 63 India Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 64 India Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 65 Australia Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 66 Australia Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 67 Australia Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 68 Australia Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 69 South Korea Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 70 South Korea Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 71 South Korea Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 72 South Korea Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 73 Latin America Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 74 Latin America Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 75 Latin America Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 76 Latin America Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 77 Brazil Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 78 Brazil Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 79 Brazil Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 80 Brazil Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 81 Mexico Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 82 Mexico Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 83 Mexico Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 84 Mexico Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 85 Rest of Latin America Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 86 Rest of Latin America Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 87 Rest of Latin America Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 88 Rest of Latin America Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 89 Middle East and Africa Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 90 Middle East and Africa Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 91 Middle East and Africa Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 92 Middle East and Africa Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 93 GCC Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 94 GCC Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 95 GCC Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 96 GCC Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 97 Africa Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 98 Africa Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 99 Africa Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 100 Africa Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)
TABLE 101 Rest of Middle East and Africa Point of Care Molecular Diagnostics Market By Product & Service, 2021-2031, USD (Million)
TABLE 102 Rest of Middle East and Africa Point of Care Molecular Diagnostics Market By Technology, 2021-2031, USD (Million)
TABLE 103 Rest of Middle East and Africa Point of Care Molecular Diagnostics Market By Application, 2021-2031, USD (Million)
TABLE 104 Rest of Middle East and Africa Point of Care Molecular Diagnostics Market By End User, 2021-2031, USD (Million)

List of Figures

FIG. 1 Global Point of Care Molecular Diagnostics Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global Point of Care Molecular Diagnostics Market: Quality Assurance
FIG. 5 Global Point of Care Molecular Diagnostics Market, By Product & Service, 2022
FIG. 6 Global Point of Care Molecular Diagnostics Market, By Technology, 2022
FIG. 7 Global Point of Care Molecular Diagnostics Market, By Application, 2022
FIG. 8 Global Point of Care Molecular Diagnostics Market, By End User, 2022
FIG. 9 Global Point of Care Molecular Diagnostics Market, By Geography, 2022
FIG. 10 Market Geographical Opportunity Matrix - Global Point of Care Molecular Diagnostics Market, 2022
FIG. 11 Market Positioning of Key Point of Care Molecular Diagnostics Market Players, 2022
FIG. 12 Global Point of Care Molecular Diagnostics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
FIG. 13 Global Point of Care Molecular Diagnostics Market, By Product & Service, 2022 Vs 2031, %
FIG. 14 Global Point of Care Molecular Diagnostics Market, By Technology, 2022 Vs 2031, %
FIG. 15 Global Point of Care Molecular Diagnostics Market, By Application, 2022 Vs 2031, %
FIG. 16 Global Point of Care Molecular Diagnostics Market, By End User, 2022 Vs 2031, %
FIG. 17 U.S. Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 18 Canada Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 19 Rest of North America Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 20 UK Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 21 Germany Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 22 Spain Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 23 Italy Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 24 France Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 25 Rest of Europe Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 26 China Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 27 Japan Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 28 India Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 29 Australia Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 30 South Korea Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 31 Rest of Asia Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 32 Brazil Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 33 Mexico Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 34 Rest of Latin America Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 35 GCC Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 36 Africa Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031
FIG. 37 Rest of Middle East and Africa Point of Care Molecular Diagnostics Market (US$ Million), 2021 - 2031

Product Code: 139508-04-23

The global market for point-of-care molecular diagnostics is anticipated to expand at a CAGR of 8.5% during the forecast period of 2023 and 2031. The rise of the point-of-care molecular diagnostics market is primarily driven by the increasing prevalence of infectious diseases and cancer, as well as the growing desire of end users for point-of-care molecular testing due to its attractive features. Medical personnel has long utilized molecular diagnostics in laboratories and other healthcare settings. However, the expensive cost of testing, the time-consuming nature, and the delayed findings of molecular diagnostics has encouraged them to seek out alternative diagnostic methods. This has brought the market for molecular diagnostics at the point-of-care into the limelight. Point-of-care molecular diagnostics has acquired significant traction across end-use verticals, including hospitals and research institutes, due to its ability to cut turnaround time and deliver reliable results quickly. Molecular testing at the point of care enables the rapid and early diagnosis of illnesses in non-laboratory settings. Typically, these tests are administered at the locations of close patients.

A key factor driving the growth of the point-of-care molecular diagnostics market is the increasing adoption of point-of-care molecular diagnostic solutions for the early detection of a wide range of diseases, from respiratory diseases and cancer to sexually transmitted diseases and gastrointestinal disorders. In the future years, the rapid expansion of the molecular diagnostics and molecular imaging markets, fueled by rising health consciousness in emerging nations, will generate possibilities for point-of-care molecular diagnostics producers. In addition, recent advances in microfluidics and genetic sequencing, along with the development of low-cost and speedy point-of-care molecular diagnostic platforms, will increase sales of POC molecular diagnostics devices, thereby growing the market for molecular POC tests.

Rising Frequency of Infectious and Malignant Diseases

The rising incidence of infectious diseases and cancer in both developed and emerging regions will favorably impact the growth of the market for point-of-care molecular diagnostics. The increasing frequency of prescriptions for molecular diagnostic tests is attributable to the diagnosis and treatment of such disorders. Demand for point-of-care molecular diagnostics is anticipated to be driven over the projected period by the aforementioned causes and the growing trend toward preventive medicine.

Opportunities For Expansion in Emerging Nations

Emerging economies such as India, South Korea, Brazil, and Mexico present substantial growth potential to market participants in the point-of-care molecular diagnostics sector. This is due to low regulatory hurdles, advancements in healthcare infrastructure, a growing patient population, an increase in the prevalence of infectious diseases, and rising healthcare expenditures. In addition, the regulatory policies of several of these nations are more adaptable and business-friendly than those of developed nations.

Unfavorable Reimbursement Scenario to Limit the Market Growth

Inadequate reimbursements are a major factor inhibiting the growth of the market for molecular diagnostics at the point of care. Getting Medicare and private health insurers to pay for diagnostic testing is a significant obstacle to the commercialization of most diagnostic tests. In 2018, Medicare in the United States updated its funding process for several IVD tests, including point-of-care molecular diagnostics. Several of these tests are billed using unlisted Healthcare Common Procedure Coding System (HCPCS) codes. In such instances, Medicare Administrative Contractors (MACs) establish a payment amount for their respective local governments. CMS cut the Medicare payment rate for COVID-19 tests based on high throughput technology to USD 75 unless laboratories can process findings in less than two days. Medicare does not currently fund genetic testing for those without a cancer family history (Source: American Society of Clinical Oncology).

Infectious Diseases Led the Market by Application

PoC testing in molecular diagnostics has many uses, including testing near the patient in infectious disease management, oncology, hematology, prenatal screening, and endocrinology. In the disciplines of infectious illnesses and oncology, point-of-care (PoC) molecular testing has seen the greatest application-based advancements. In 2022, the infectious diseases segment had the biggest revenue share. Contributing to the revenue share of infectious diseases for rapid molecular diagnostic tests are the provision and facilitation of appropriate antibiotic therapy, faster disease management, enhanced distribution of healthcare laboratory assets, and reductions in mortality and healthcare expenditures.

PCR Based Testing Led the Market by Technology

On the basis of technology, the market for point-of-care molecular diagnostics has been divided into PCR-based, genetic sequencing-based, hybridization-based, and microarray-based tests and devices. In 2022, PCR-based testing generated the greatest revenue share. The market will be driven by the commercialization of point-of-care diagnostics that deliver accurate, rapid real-time PCR analysis for infectious illnesses such as H1N1 and influenza. Due to a number of industry advances, NGS-based molecular testing in close proximity to the patient is expected to have substantial growth during the projection period. Innovative platform modifications that enable genetic sequencing and DNA data processing at the point of care with high precision and give speedy diagnosis contribute to the predicted growth of this market sector. Rapid DNA analysis is anticipated to have substantial growth in the next years as a result of the continuing innovation and R&D efforts of market leaders.

OTC Tests to Dominate During the Forecast Period for Market by Test Site

The market is divided into Proof-of-Concept (PoC) and Over-the-Counter (OTC) tests, depending on the location of the tests. The versatility and portability of OTC tests are superior to POC tests for use in homes and assisted care facilities. The majority of OTC users are untrained professionals and, in the majority of cases, the patients themselves. In addition, a number of these testing instruments are exempt from CLIA, which encourages their use outside of laboratories. Over-the-counter (OTC) tests are anticipated to create more revenue during the projected period due to their usability, accessibility, and higher adoption rate.

Decentralized Laboratories Led the Market by End User

The market is segmented by end-use into decentralized laboratories, hospitals, home care, and assisted living healthcare facilities, among others. In 2022, decentralized laboratories generated the greatest revenue share. The ability of these tests to provide speedy and accurate molecular analysis with a substantially smaller physical footprint than their central laboratory-based equivalents is a crucial driver in the segment's greater revenue share.

APAC to Remain the Fastest Growing Region

Continuous efforts by big market participants to bolster their market position are a significant contributor to the majority share. In addition, a number of clinical studies examining the efficacy and precision of novel molecular tests are anticipated to contribute to the expansion of the market throughout the forecast period. The growing need for speedy diagnosis and the introduction of innovative molecular diagnostic procedures for DNA analysis has positioned Europe as a significant market niche. Due to a lack of advanced central laboratory testing services, a bigger population base requiring clinical testing, and the potential cost-effective implementation of PoC molecular assays, Asia Pacific is predicted to experience the highest growth rate over the forecast period.

Innovations Remain as the Key to Enhance Market Shares

Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux S.A. (France), Danaher Corporation (U.S.), Quidel Corporation (U.S.), QIAGEN N.V. (Netherlands), Co-Diagnostics, Inc. Biocartis NV (Belgium), Meridian Bioscience, Inc. (U.S.), and Thermo Fisher Scientific, Inc. (U.S.). These firms are continually concentrating on the development of innovative point-of-care molecular diagnostic platforms, such as the point-of-care molecular COVID test and paper-based nucleic acid amplification assays, which may diagnose diseases with relative simplicity. In addition, they have utilized techniques such as mergers, acquisitions, and alliances, among others, to increase its global presence.

In March 2020, Abbott Laboratories will release the ID NOW point-of-care test for coronavirus detection.

In July 2021, QuantuMDx introduced Q-POCTM, a fast PCR diagnostic technology for the point of care.

Co-Diagnostics, a molecular diagnostics company, successfully acquired Idaho Molecular and Advanced Conceptions in 2022.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Point of Care Molecular Diagnostics market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Point of Care Molecular Diagnostics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Product & Service

Assays & kits
Instruments &Analyzers
Software & Services

Technology

RT-PCR
INAAT
Other technologies

Application

Respiratory Diseases
Sexually Transmitted Diseases
Hospital-acquired Infections
Cancer
Hepatitis
Gastrointestinal Disorders
Other Applications

End User

Physicians' Offices
Hospitals & ICUs
Research Institutes
Other End Users

Region Segment (2021-2031; US$ Million)

North America
- U.S.
- Canada
- Rest of North America

UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe

Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America

Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Point of Care Molecular Diagnostics market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Point of Care Molecular Diagnostics market?

Which is the largest regional market for Point of Care Molecular Diagnostics market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Point of Care Molecular Diagnostics market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Point of Care Molecular Diagnostics market worldwide?

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global Point of Care Molecular Diagnostics Market
2.2. Global Point of Care Molecular Diagnostics Market, By Product & Service, 2022 (US$ Million)
2.3. Global Point of Care Molecular Diagnostics Market, By Technology, 2022 (US$ Million)
2.4. Global Point of Care Molecular Diagnostics Market, By Application, 2022 (US$ Million)
2.5. Global Point of Care Molecular Diagnostics Market, By End User, 2022 (US$ Million)
2.6. Global Point of Care Molecular Diagnostics Market, By Geography, 2022 (US$ Million)
2.7. Attractive Investment Proposition by Geography, 2022

3. Point of Care Molecular Diagnostics Market: Competitive Analysis

3.1. Market Positioning of Key Point of Care Molecular Diagnostics Market Vendors
3.2. Strategies Adopted by Point of Care Molecular Diagnostics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031

4. Point of Care Molecular Diagnostics Market: Macro Analysis & Market Dynamics

4.1. Introduction
4.2. Global Point of Care Molecular Diagnostics Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)

5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
- 5.3.1. Assays & kits
- 5.3.2. Instruments &Analyzers
- 5.3.3. Software & Services

6. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)

6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
- 6.3.1. RT-PCR
- 6.3.2. INAAT
- 6.3.3. Other technologies

7. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)

7.1. Market Overview
7.2. Growth & Revenue Analysis: 2022 Versus 2031
7.3. Market Segmentation
- 7.3.1. Respiratory Diseases
- 7.3.2. Sexually Transmitted Diseases
- 7.3.3. Hospital-acquired Infections
- 7.3.4. Cancer
- 7.3.5. Hepatitis
- 7.3.6. Gastrointestinal Disorders
- 7.3.7. Other Applications

8. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)

8.1. Market Overview
8.2. Growth & Revenue Analysis: 2022 Versus 2031
8.3. Market Segmentation
- 8.3.1. Physicians' Offices
- 8.3.2. Hospitals & ICUs
- 8.3.3. Research Institutes
- 8.3.4. Other End Users

9. North America Point of Care Molecular Diagnostics Market, 2021-2031, USD (Million)

9.1. Market Overview
9.2. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
9.3. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
9.4. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
9.5. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
9.6.Point of Care Molecular Diagnostics Market: By Region, 2021-2031, USD (Million)
- 9.6.1.North America
  - 9.6.1.1. U.S.
    - 9.6.1.1.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 9.6.1.1.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 9.6.1.1.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 9.6.1.1.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 9.6.1.2. Canada
    - 9.6.1.2.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 9.6.1.2.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 9.6.1.2.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 9.6.1.2.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 9.6.1.3. Rest of North America
    - 9.6.1.3.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 9.6.1.3.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 9.6.1.3.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 9.6.1.3.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)

10. UK and European Union Point of Care Molecular Diagnostics Market, 2021-2031, USD (Million)

10.1. Market Overview
10.2. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
10.3. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
10.4. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
10.5. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
10.6.Point of Care Molecular Diagnostics Market: By Region, 2021-2031, USD (Million)
- 10.6.1.UK and European Union
  - 10.6.1.1. UK
    - 10.6.1.1.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 10.6.1.1.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 10.6.1.1.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 10.6.1.1.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 10.6.1.2. Germany
    - 10.6.1.2.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 10.6.1.2.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 10.6.1.2.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 10.6.1.2.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 10.6.1.3. Spain
    - 10.6.1.3.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 10.6.1.3.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 10.6.1.3.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 10.6.1.3.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 10.6.1.4. Italy
    - 10.6.1.4.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 10.6.1.4.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 10.6.1.4.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 10.6.1.4.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 10.6.1.5. France
    - 10.6.1.5.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 10.6.1.5.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 10.6.1.5.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 10.6.1.5.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 10.6.1.6. Rest of Europe
    - 10.6.1.6.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 10.6.1.6.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 10.6.1.6.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 10.6.1.6.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)

11. Asia Pacific Point of Care Molecular Diagnostics Market, 2021-2031, USD (Million)

11.1. Market Overview
11.2. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
11.3. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
11.4. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
11.5. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
11.6.Point of Care Molecular Diagnostics Market: By Region, 2021-2031, USD (Million)
- 11.6.1.Asia Pacific
  - 11.6.1.1. China
    - 11.6.1.1.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 11.6.1.1.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 11.6.1.1.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 11.6.1.1.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 11.6.1.2. Japan
    - 11.6.1.2.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 11.6.1.2.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 11.6.1.2.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 11.6.1.2.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 11.6.1.3. India
    - 11.6.1.3.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 11.6.1.3.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 11.6.1.3.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 11.6.1.3.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 11.6.1.4. Australia
    - 11.6.1.4.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 11.6.1.4.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 11.6.1.4.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 11.6.1.4.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 11.6.1.5. South Korea
    - 11.6.1.5.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 11.6.1.5.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 11.6.1.5.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 11.6.1.5.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 11.6.1.6. Rest of Asia Pacific
    - 11.6.1.6.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 11.6.1.6.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 11.6.1.6.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 11.6.1.6.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)

12. Latin America Point of Care Molecular Diagnostics Market, 2021-2031, USD (Million)

12.1. Market Overview
12.2. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
12.3. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
12.4. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
12.5. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
12.6.Point of Care Molecular Diagnostics Market: By Region, 2021-2031, USD (Million)
- 12.6.1.Latin America
  - 12.6.1.1. Brazil
    - 12.6.1.1.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 12.6.1.1.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 12.6.1.1.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 12.6.1.1.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 12.6.1.2. Mexico
    - 12.6.1.2.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 12.6.1.2.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 12.6.1.2.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 12.6.1.2.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 12.6.1.3. Rest of Latin America
    - 12.6.1.3.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 12.6.1.3.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 12.6.1.3.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 12.6.1.3.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)

13. Middle East and Africa Point of Care Molecular Diagnostics Market, 2021-2031, USD (Million)

13.1. Market Overview
13.2. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
13.3. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
13.4. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
13.5. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
13.6.Point of Care Molecular Diagnostics Market: By Region, 2021-2031, USD (Million)
- 13.6.1.Middle East and Africa
  - 13.6.1.1. GCC
    - 13.6.1.1.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 13.6.1.1.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 13.6.1.1.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 13.6.1.1.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 13.6.1.2. Africa
    - 13.6.1.2.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 13.6.1.2.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 13.6.1.2.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 13.6.1.2.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)
  - 13.6.1.3. Rest of Middle East and Africa
    - 13.6.1.3.1. Point of Care Molecular Diagnostics Market: By Product & Service, 2021-2031, USD (Million)
    - 13.6.1.3.1. Point of Care Molecular Diagnostics Market: By Technology, 2021-2031, USD (Million)
    - 13.6.1.3.1. Point of Care Molecular Diagnostics Market: By Application, 2021-2031, USD (Million)
    - 13.6.1.3.1. Point of Care Molecular Diagnostics Market: By End User, 2021-2031, USD (Million)

14. Company Profile

14.1. Abbott Laboratories (U.S.)
- 14.1.1. Company Overview
- 14.1.2. Financial Performance
- 14.1.3. Product Portfolio
- 14.1.4. Strategic Initiatives
14.2. F. Hoffmann-La Roche Ltd. (Switzerland)
- 14.2.1. Company Overview
- 14.2.2. Financial Performance
- 14.2.3. Product Portfolio
- 14.2.4. Strategic Initiatives
14.3. bioMerieux S.A. (France)
- 14.3.1. Company Overview
- 14.3.2. Financial Performance
- 14.3.3. Product Portfolio
- 14.3.4. Strategic Initiatives
14.4. Danaher Corporation (U.S.)
- 14.4.1. Company Overview
- 14.4.2. Financial Performance
- 14.4.3. Product Portfolio
- 14.4.4. Strategic Initiatives
14.5. Quidel Corporation (U.S.)
- 14.5.1. Company Overview
- 14.5.2. Financial Performance
- 14.5.3. Product Portfolio
- 14.5.4. Strategic Initiatives
14.6. QIAGEN N.V. (Netherlands)
- 14.6.1. Company Overview
- 14.6.2. Financial Performance
- 14.6.3. Product Portfolio
- 14.6.4. Strategic Initiatives
14.7. Co-Diagnostics, Inc.
- 14.7.1. Company Overview
- 14.7.2. Financial Performance
- 14.7.3. Product Portfolio
- 14.7.4. Strategic Initiatives
14.8. Biocartis NV (Belgium)
- 14.8.1. Company Overview
- 14.8.2. Financial Performance
- 14.8.3. Product Portfolio
- 14.8.4. Strategic Initiatives
14.9. Meridian Bioscience, Inc. (U.S.)
- 14.9.1. Company Overview
- 14.9.2. Financial Performance
- 14.9.3. Product Portfolio
- 14.9.4. Strategic Initiatives
14.10. Thermo Fisher Scientific, Inc. (U.S.)
- 14.10.1. Company Overview
- 14.10.2. Financial Performance
- 14.10.3. Product Portfolio
- 14.10.4. Strategic Initiatives
14.11. Others
- 14.11.1. Company Overview
- 14.11.2. Financial Performance
- 14.11.3. Product Portfolio
- 14.11.4. Strategic Initiatives